Open Access<p>Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)</p>
Author(s) -
Chia-Hung Lin,
Hui Yang,
Ping Kun Chen,
Shi-Heng Wang,
Hsien Yuan Lane
Publication year - 2020
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s234371
Subject(s) - medicine , dementia , sodium benzoate , psychiatry , pathology , disease
Behavioral and psychological symptoms of dementia (BPSD) are associated with poorer prognosis of dementia. A 24-week study demonstrated that sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, surpassed placebo in improving cognitive function in early-phase Alzheimer's disease; however, benzoate did not excel placebo in another 6-week study on BPSD. The current study examined whether the precision medicine approach was able to identify specific individuals with BPSD who could benefit from benzoate treatment.